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part of the gastrointestinal tract. Although most people with CD lead active lives, five 
years after onset 15% to 20% of patients are disabled by their disease to some degree. 
The purpose of the current review was to evaluate recent data from the literature on 
the economic burden of CD in European countries in adults and in children, using US 
data as a benchmark. Methods: A systematic review of the data on economic and 
humanistic burden for adults and children in Germany, France, UK, Italy, Spain and 
the US was performed covering the period 2000 to 2012. The methods followed rec-
ommendations and guidance published by the Centre for Reviews & Dissemination, 
York, UK. Results: Of the 425 publications identified on the economic burden of 
CD, 92 were suitable for further evaluation, and 39 were selected. Among these 
studies, five presented total costs of CD management in adults, ranging from € 1,425 
to € 15,521 per patient depending on the country. Most of the direct costs were due 
to hospitalisations, surgeries or use of biologic drugs. Patients with severe disease 
and those requiring hospitalisation had disproportionately higher costs (5.6 times 
higher) compared to those with milder disease. Direct costs were more important 
for relapsing disease than quiescent disease. Only one European study focused on 
children using biologic drugs as maintenance treatment. ConClusions: Research 
on the economic burden of CD management has been mainly published on adults 
in the US and UK, with limited data from Germany, Spain and Italy. Similar data for 
paediatric CD is almost non-existent. More research is needed to better understand 
the economic and humanistic burden faced by paediatric CD patients in Europe.
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objeCtives: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-
alcoholic fatty liver disease that becomes increasingly prevalent with the growing 
epidemic of obesity and diabetes in the United States. An estimated 3% of adults in the 
US have NASH and are at high risk of severe liver complications, including cirrhosis, 
liver failure, and hepatocellular carcinoma (HCC). Despite the rising prevalence, data 
on its economic and clinical consequences are limited. The objective of this study 
was to predict the long-term clinical and economic consequences associated with 
the adult NASH patients in the US over the next 20 years, including NASH-related 
complications, morbidity, mortality and health care costs. Methods: We developed 
a Markov cohort model to estimate the consequences of NASH, which included six 
Markov states: NASH, compensated cirrhosis, decompensated cirrhosis, HCC, liver 
transplantation, and death. We estimated the number of liver complications, their 
associated health care costs, and NASH-related mortality. Results: By 2033, 53.1% 
and 32.8% of NASH patients would progress to compensated and decompensated cir-
rhosis, respectively. An estimated 13.7% of patients developed HCC, and 13.3% eventu-
ally underwent liver transplantation. Among NASH patients, 16% had Type II diabetes 
and 44.8% and 23.8% would develop decompensated cirrhosis and HCC. The model 
predicted hepatic-related mortality of 24.2% and 12.6% for patients with and without 
diabetes, while the cardiovascular-related mortality was estimated to be 12.1% and 
8.8% for NASH patients with and without diabetes. The direct health care cost was 
estimated at $72,170 and $120,165 for patients with and without diabetes, resulting in 
a total of $574 billion health care cost over the next 20 years. ConClusions: NASH 
patients were expected to have substantial risks for chronic liver failure and result 
in an increasing financial burden on the US health care system.
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objeCtives: Undertake an economic evaluation of transjugular intrahepatic por-
tosystemic shunts (TIPS) compared to large volume paracentesis (LVP) in patients 
with refractory ascites. Paracentesis, although the standard treatment for refractory 
ascites, does not treat the underlying portal hypertension. According to a meta-
analysis of individual patient data, using TIPS with bare metal stents (BMS) rather 
than LVP showed improved survival and lower recurrence of ascites although with 
a higher number of hepatic encephalopathy episodes (Salerno 2007). Methods: A 
Markov economic model was developed to measure the incremental resources and 
costs associated with TIPS, using costs for ePTFE covered stent-grafts configured 
for TIPS (SG), compared to LVP over two years. Clinical data came mainly from the 
meta-analysis, whilst health care costs were from UK national databases. Results: 
Use of TIPS rather than LVP to manage refractory ascites was estimated to save 
almost £1,600 per patient over 2 years. Total costs for the treatment pathway were 
£8,310 with TIPS and £9,907 with LVP treatments. The TIPS implantation, together 
with the associated costs of re-intervention & complications cost £6,760 but there 
were estimated savings of £8,360 from avoided LVP procedures. Using TIPS to man-
age refractory ascites, rather than LVP, was cost saving under all the sensitivity 
analyses undertaken. ConClusions: The economic model demonstrated a total 
cost reduction of £1,600 per patient from TIPS with SG compared to LVP. Actual cost 
reduction may be greater as clinical data used from the meta-analysis was for BMS. 
Compared to BMS, SG have improved patency resulting in fewer reinterventions 
(Bureau 2007) which may reduce overall costs.
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were estimated using national average reference costs based on treatment speci-
ality. Costs of medications prescribed in secondary care were not included. Total, 
mean and annual visits and costs were estimated and stratified by gender, age and 
treatment speciality. Prices were adjusted to 2011/2012. Results: We identified 
79,303 patients with IBS with an average follow-up of 3.38 years. Of these patients, 
46,814(59%) had ≥ 1 contact with secondary care for any cause; 22,685(48.5%) patients 
attended outpatient services only. Patients using secondary care had about 2 hos-
pitalizations on average and 3-4 outpatient visits annually. Mean inpatient stay 
declined from 4 days in 2008/2009 to 3 days in 2011/2012. The total cost of hospi-
talisation during the period was over £114 million, including about £35(30%) million 
for emergency inpatient admissions and £33.8 million for outpatient attendance. 
Digestive disorders accounted for around 30% of inpatient admissions and 21% of 
expenditure incurred. Mean cost of inpatient admissions for digestive conditions 
was £1,993, average costs per patient was £4,871 and £2,779 for elective and emer-
gency visits respectively. ConClusions: Utilisation and costs of secondary care 
among IBS patients is substantial, not only for the management of IBS and related 
conditions, but also for other co-morbid medical conditions.
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objeCtives: There are approximately 40,000 Canadians living with spinal cord 
injury (SCI). Most individuals with SCI experience some type of bowel dysfunction 
(BD), which can contribute to a high burden in individuals and caregivers, and a 
decrease in quality of life. This study aims to identify and measure resources, costs, 
health preference and quality of life associated with BD and its management in a 
cohort of SCI individuals living in a community setting in Ontario over a 6-month 
period. Methods: This study is a prospective, observational study with 80 adult 
participants being recruited at three SCI clinics in Ontario, Canada. Questionnaires 
are completed by participants over a 6-month period (baseline, three weekly and 
five monthly). Information related to demographics, BD (e.g., neurogenic bowel 
dysfunction score), health preference (e.g., Health Utility Index (HUI) Mark 3) and 
resource utilization (e.g., physician, medication, caregiver burden, etc.) attributed 
to BD is being collected. Results: Results from three clinics are being evaluated. 
45 participants have completed the questionnaires to-date. The majority of partici-
pants are male (60.00%). Mean time since SCI was 20.2±13.7 (2 – 42) years. Twenty 
(44.4%) participants were employed. At baseline, the mean neurogenic BD score was 
14.37±6.05 (0 – 31). At 6 months, the score was 12.9±6.6 (2 – 28). The mean HUI-3 score 
at baseline was 0.17±0.31 (-0.37 – 0.95). At 6 months the score was 0.19±0.33 (-0.37 – 
1). The mean number of visits to primary care physicians by participants was 8.3 ± 
8.6 (0 – 33) times over 6 months. 52.21% of participants required caregiver assistance. 
12.50% of participants required a mean 1.21±0.67 (0.3 – 2) hours daily assistance 
with their bowel routines. ConClusions: Results from the 45 SCI individuals with 
BD indicate a variety of health resources are being utilized over a 6-month period. 
Future results will have resources associated with BD quantified.
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objeCtives: Hepatitis C virus infection is accompanied by significant disease and 
economic burden internationally. In absence of data, the objective of this study 
was to estimate the annual cost of hepatitis C treatment and follow-up, in Greece, 
according to disease severity. Methods: Resource utilization for “typical patient” 
scenarios, according to disease stage, was elicited via an expert panel (gastroen-
terologists and hepatologists from major hospital units of the Greek NHS). Patients 
were stratified based on disease stages; (a) fibrosis stage F0 to F3, (METAVIR score) (b) 
compensated cirrhosis (c) decompensated cirrhosis – first year (d) decompensated 
cirrhosis – subsequent years (e) hepatocellular carcinoma (HCC) (f) liver transplant 
(LT) – first year (g) LT – subsequent years. Direct cost categories included yearly 
costs of consultations, laboratory and PCR tests, medications and hospitalization. 
Cost calculations were based on 2012 fixed fees and prices, from a Social Security 
perspective. Results: The average direct annual cost per patient for F0-F3 patients 
was estimated at 642.7€ , excluding the cost of medications or 12,685.1€ , includ-
ing the cost of standard of care with PegIFN/ribavirin regimen. Respective annual 
costs for states (b) to (g) were: 636.7€ (compensated cirrhosis), 2,250.1€ and 5,934.5€ 
(decompensated first and subsequent years), 21,890.1€ (HCC), 35,051.1€ and 4,001.5€ 
(LT first and subsequent years). Main cost variables were hospitalizations [48.9%, 
53.3% and 88.2% of the total cost for states (c) (d) and (g)], medications [93.2% and 
50.1% of the total cost for states (e) and (g)] and laboratory tests [89.1% and 83.0% 
of the total cost for states (a) and (b)]. ConClusions: This cost analysis of chronic 
hepatitis C in the Greek health care system has shown that there is a substantial 
economic burden, significantly increasing in advanced liver disease. Standard and 
new interventions that slow disease progression or achieve virus eradication are 
deemed necessary from a clinical and economic perspective.
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objeCtives: Crohn’s Disease (CD) is an immune-mediated disorder characterised by 
recurrent chronic uncontrolled inflammation on the intestinal mucosa affecting any 
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objeCtives: Presently, linaclotide is the only EMA approved therapy indicated for 
the treatment of irritable bowel syndrome with constipation (IBS-C). This study 
sought to determine the cost-effectiveness of linaclotide compared to antidepres-
sants for the treatment of adults with moderate to severe IBS-C who have previ-
ously received antispasmodics and/or laxatives from the perspective of the Scottish 
National Health System (NHS). Methods: A Markov model was created to estimate 
costs and QALYs over a 5-year time horizon from the perspective of NHS Scotland. 
Health states were based on treatment satisfaction (satisfied, moderately satisfied, 
not satisfied) and death. Transitions between states were based on satisfaction data 
from the linaclotide pivotal studies (MCP-103-302 and LIN-MD-31) and Scottish 
general all-cause mortality statistics. Treatment costs were calculated from the 
British National Formulary. NHS resource use and disease-related costs for each 
health state were estimated from Scottish clinician interviews in combination with 
NHS Reference costs. Quality of life was based on EQ-5D data collected from the 
pivotal studies. Costs and QALYs were discounted at 3.5% per annum. Uncertainty 
was explored through extensive deterministic and probabilistic sensitivity analy-
ses. Results: Over a 5-year time horizon, the additional costs and QALYs with 
linaclotide were £659 and 0.089, resulting in an incremental cost-effectiveness ratio 
of £7,370 per QALY versus antidepressants. Results were most sensitive to health 
state transitions probabilities, NHS resource use assumptions and health state 
utilities. Threshold analyses showed that the effectiveness of linaclotide would 
have to be at least 11% lower than the base case to exceed a willingness-to-pay 
threshold (WTP) of £20,000 per QALY. Based on the probabilistic sensitivity analysis, 
the likelihood that linaclotide was cost-effective at a WTP of £20,000 per QALY was 
74%. ConClusions: Linaclotide is a cost-effective treatment for adults with mod-
erate to severe IBS-C who have previously received antispasmodics and/or laxatives.
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objeCtives: To assess the cost-effectiveness of treating chronic HCV infection 
(genotype 1) with currently available telaprevir+pegylated interferon alpha/ribavirin 
(TPR) compared to waiting for new regimens with improved efficacy (hypothetical 
treatment assumed) currently in development from the French health care perspec-
tive. Methods: A Markov model tracked the adult naïve HCV+ French population 
over a lifetime horizon. Model health-states are defined by METAVIR fibrosis stage 
(F0-F4) and complications of advanced HCV (decompensated cirrhosis, hepatocel-
lular carcinoma, liver transplant, and death). During each 1-year cycle, individu-
als may remain in the current health-state, respond to treatment or progress, at 
probabilities determined by disease status, age at infection, current age, gender, 
and treatment received. Individuals were eligible for treatment in F2-F4. Transition 
probabilities, treatment efficacy, health-state utilities, resource utilization and costs 
were derived from published literature and standard French sources. The efficacy 
of a new hypothetical treatment regimen was based on currently published results; 
cost for the new treatment was assumed at € 50,000 for a full treatment (excluding 
PR backbone). Results: A treatment lag of 1, 2, and 3 years resulted in 142,777 indi-
viduals, 140,417 individuals, and 137,930 individuals being treated by the new regi-
men, respectively, versus 145,010 with immediate TPR treatment. The new treatment 
option resulted in additional life years saved (range 11,230-27,536), QALYs gained 
(range 12,528-29,359), and prevented more HCV-related deaths (range 3,839-5,756). 
Total costs incurred were higher for the new regimen versus TPR, from the health 
care perspective. ICERs were € 58,294.49/QALY, € 73,295.59/QALY, and € 107,403.02/
QALY gained for a 1, 2, and 3 year treatment lag, respectively. ConClusions: These 
findings suggest waiting for new regimens currently in development should not be 
the most efficient choice to be considered by French Health care system. Waiting 
for new treatments should yield better clinical outcomes, but with higher costs and 
ICERS that may be challenging for the payer.
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objeCtives: This study had a dual objective: verify the improvements in qual-
ity of life (QoL) due to biological drugs administration and evaluate their cost-
effeffectiveness versus the standard steroid-based therapy in Crohn’s Disease 
(CD). High-cost biological drugs’ efficacy is well-established, but they still lack of 
cost-effectiveness studies. Methods: A survey was prepared with clinicians and 
pharmacoeconomists and administered in 9 centers in Italy. The questionnaire 
was set up to detect QoL through a Visual Analogue Scale and EQ-5D and to assess 
patients’ profile (age, gender, job) and clinical features (time-to-first diagnosis, cur-
rent and at-diagnosis Montreal classification, current and at-diagnosis treatments, 
past surgical procedures, hospitalizations). Collected data were then used in a sta-
tistical regression model and an economic assessment complete of probabilistic 
sensitivity analysis was performed comparing costs and utilities of the considered 
treatments. Results: A total of 348 questionnaires were collected, giving back a 
objeCtives: Establish the potential resource and cost savings from using ePTFE 
covered stent-grafts configured for TIPS (SG) compared to bare metal stents (BMS). 
Most centres have adopted SGs to treat portal hypertension because of their 
reduced re-intervention rates, elimination of regular monitoring of patency and 
improved survival. However there is no published economic analysis identifying 
the related cost consequences. Understanding the improved efficiencies is essen-
tial in the current financial environment. Methods: A Markov economic model 
was developed to measure the incremental costs of the initial procedure and 
re-interventions with SG compared to BMS. Re-intervention procedures included 
angioplasty (67%), introducing a balloon expandable stent (22%) or a second stent 
(10%). The adverse events were hepatic encephalopathy and clinical relapse. 
Clinical data came mainly from a published RCT (Bureau 2007), whilst health care 
costs were from UK national databases. Results: Compared to BMS, using SG in 
TIPS resulted in a cost saving of over £1,150 per patient over 2 years. Modelling 100 
patients, compared to BMS, the SG cohort had 25 fewer re-interventions including 
angioplasties, saving 41 hours staff time in theatre and 16 inpatient days; with 
fewer cases of encephalopathy (16), recurrent ascites (8), variceal bleeds (5) and a 
markedly reduced mortality (13). ConClusions: The model showed that ePTFE 
covered stent-grafts configured for TIPS reduced mortality and re-interventions, 
saved theatre time and bed-days, and reduced overall costs despite the higher 
initial device cost.
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objeCtives: In 2011 EMA approved Boceprevir and Telaprevir with PegIFN and 
Ribavirin for the treatment of Genotype 1 Chronic Hepatitis C patients. In 2013 
the Greek and other European HCV Guidelines recommend treatment alloca-
tion in G1 naïve patients according to the IL28B genotype or the RVR profile. 
Local studies indicate that the IL28B-CC and the RVR (+) rates are approximately 
30%. The objective of this study was to implement this guidance and examine 
whether triple therapy with PegIFNa-2a+RBV and the two protease inhibitors, 
Boceprevir or Telaprevir, constitutes a cost-saving option for the treatment of 
naïve G1 patients in the Greek health care setting. Methods: For the needs 
of this analysis, a cost-consequence model was utilized, to compare the costs 
incurred when: i) patients with IL28B CC aplotype (30%) were treated with SoC 
(PegIFN alfa-2a + RBV) and patients with IL28B non-CC aplotypes (70%) were 
treated with triple therapy and ii) all patients are treated with triple therapy. 
The economic inputs are based on official and publically available sources while 
the clinical inputs are taken from published clinical trial results. The number of 
patients treated per year was provided by local bibliography. Results: The total 
cost to treat 509 naïve patients with triple therapy was € 13,8 million compared to 
€ 10.9 million to treat based on IL28B allocation, maintaining the same SVR rate 
of 70% for either of the treatment strategies. ConClusions: This personalized 
approach based on a baseline predictor of response such as the IL28B profile was 
proven to be a cost-saving resource allocation choice compared to the option 
of treating all treatment naive patients with triple therapy, providing SVR rates 
of 70% and a constrain of cost for the Greek health care system of € 2,9 million/
year (aprox.25%).
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objeCtives: To assess the cost-effectiveness of treating HCV infection (geno-
type 1) with telaprevir/pegylated interferon alpha/ribavirin (TPR) at METAVIR 
fibrosis stage F2 (“early”) versus delaying treatment until progression to F3 
(“delayed”) from the French health care perspective. Methods: A Markov 
model tracked the HCV+ French population aged 40+ over a lifetime horizon to 
compare outcomes of early versus delayed treatment. Model health states are 
defined by fibrosis stage (F0-F4) and complications of advanced HCV includ-
ing decompensated cirrhosis, hepatocellular carcinoma, liver transplant, and 
death. During each 1-year cycle, individuals may remain in the current health 
state, respond to treatment or progress, at probabilities determined by disease 
status, age at infection, current age, gender, and treatment received. Transition 
probabilities, treatment efficacy, health-state utilities, resource utilization and 
costs were derived from published literature and standard French sources. Costs 
and outcomes were discounted at 4.0% for 30 years and 2% thereafter. Cost-
effectiveness was assessed as incremental cost per life year gained (LYG) and 
QALY gained. Results: An estimated 203,644 French residents aged 40+ years 
are diagnosed with HCV in 2013. Treating with TPR at F2 versus F3 is projected 
to result in 135,240 versus 113,728 individuals treated, at an incremental life-
time cost of € 654.65M from the French health care perspective. Early treatment 
avoided 2,205 HCV-related deaths and saved 11,384 life-years, and 17,599 QALYs, 
at a cost of € 57,506/LYG and € 37,197/QALY gained. Results are most sensitive to 
efficacy parameters, time horizon, and discount rates and least sensitive to diag-
nosis and treatment parameters. ConClusions: Treating HCV-infected indi-
viduals at F2 is expected to results in better clinical outcomes but at higher cost 
compared to delaying treatment until the individual progresses to F3. Earlier 
treatment with TPR should be considered as an efficient choice by the French 
health care system based on its estimated incremental cost-effectiveness ratio 
of € 37,197/QALY gained.
